5-HT1A agonists for levodopa-induced dyskinesia in Parkinson's disease.

Abstract

Levodopa is the most effective agent for treating the symptoms of Parkinson's disease (PD). However, levodopa-induced dyskinesia remains a significant complication that manifests after few years of treatment, for which therapeutic options remain limited. Several agonists of the serotonin type 1A (5-HT1A) receptor with varying levels of efficacy and interaction at other sites, have been tested in the clinic. Clinical trials testing 5-HT1A agonists have yielded inconsistent results in alleviating dyskinesia, especially that the antidyskinetic benefit observed was often accompanied by an adverse effect on motor function. In this article, we summarize and analyze the various clinical trials performed with 5-HT1A agonists in PD patients with dyskinesia and offer perspectives on the future of this class of agents in PD.

• Authors: Jawad Al-Kassmy, Christine Sun, Philippe Huot
• Journal: Neurodegenerative disease management (Neurodegener Dis Manag) Vol. 13 Issue 2 Pg. 101-112 (04 2023) ISSN: 1758-2032 [Electronic] England
• PMID: 37140165 (Publication Type: Journal Article, Review)

Chemical References

• Levodopa
• Serotonin
• Serotonin 5-HT1 Receptor Agonists
• Antiparkinson Agents

Topics

• Humans
• Levodopa (adverse effects)
• Parkinson Disease (complications, drug therapy)
• Serotonin
• Dyskinesia, Drug-Induced (drug therapy, etiology)
• Serotonin 5-HT1 Receptor Agonists (therapeutic use, pharmacology)
• Antiparkinson Agents (adverse effects)